CRNX Crinetics
- 48.000
- -1.420-2.87%
- 48.000
- 0.0000.00%
Crinetics News
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Solid Returns of 196% Over the Past Three Years
Crinetics(CRNX.US) Officer Sells US$5.31 Million in Common Stock
$Crinetics(CRNX.US)$ Officer Struthers Richard Scott sold 107.45K shares of common stock on May 8, 2024 at an average price of $49.4 for a total value of $5.31 million.Source: Announcement What is sta
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted n
Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing
Richard Scott Struthers, Director, President & CEO, on May 08, 2024, sold 107,448 shares in Crinetics Pharmaceuticals (CRNX) for $5,307,931. Following the Form 4 filing with the SEC, Struthers has con
Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Buy Rating for Crinetics Pharmaceuticals: Strong Financials and Promising Clinical Data
Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report). The associated price target was raised to $69.00.
J.P. Morgan Securities: The Crinetics Pharmaceuticals (CRNX.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $80.00.
J.P. Morgan Securities: The Crinetics Pharmaceuticals (CRNX.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $80.00.
Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and maintains $80 price target.
Form 144 | Crinetics(CRNX.US) Officer Proposes to Sell 148.29K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Crinetics(CRNX.US)$ Officer Betz Stephen F. intends to sell 3,000 shares of its common stock on May 10, with a total market value of approximately $148.29K. Source:
Buy Rating Affirmed for Crinetics Pharmaceuticals on Strong Drug Pipeline and Market Potential
Crinetics | 10-Q: Quarterly report
Crinetics Pharmaceuticals (CRNX.US): The 2024 Q1 financial report achieved revenue of US$640,000, previous value of US$2.679 million, expected value of US$260,000; earnings per share were -0.93 USD, previous value of -0.85 USD, and expected value of -0.81
Crinetics Pharmaceuticals (CRNX.US): The 2024 Q1 financial report achieved revenue of US$640,000, previous value of US$2.679 million, expected value of US$260,000; earnings per share were -0.93 USD, previous value of -0.85 USD, and expected value of -0.81 USD.
Crinetics Pharmaceuticals Q1 2024 GAAP EPS $(0.93) Misses $(0.81) Estimate, Sales $640.000K Beat $255.556K Estimate
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.81) by 14.81 percent. This is a 9.41 percent decrease over los
Crinetics Pharmaceuticals: Cash, Cash Equivalents and Short-Term Investments Sufficient to Fund Ops Into 2028 >CRNX
Crinetics Pharmaceuticals: Cash, Cash Equivalents and Short-Term Investments Sufficient to Fund Ops Into 2028 >CRNX
Crinetics Pharmaceuticals Plan to Initiate Paltusotine Phase 3 Study in Carcinoid Syndrome by End of 2024 >CRNX
Crinetics Pharmaceuticals Plan to Initiate Paltusotine Phase 3 Study in Carcinoid Syndrome by End of 2024 >CRNX
Press Release: Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Late-Breaking Presentations of Initial Results From Phase 2 Studies of Atumelnant (CRN04894) in Con
Crinetics Pharmaceuticals 1Q Loss/Shr 93c >CRNX
Crinetics Pharmaceuticals 1Q Loss/Shr 93c >CRNX
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome TrialData from Phase 3 P
Crinetics Pharmaceuticals Showcases Research at ENDO 2024
Analysis
Price Target
No Data
